Janwillem Naesens
Chief Executive Officer bij Convert Pharmaceuticals SA
Profiel
Janwillem Naesens is currently the Chief Executive Officer & Director at Convert Pharmaceuticals SA, Director at Cristal Delivery BV, Director at OCTIMET Oncology NV, Director at Highlight Therapeutics SL, Director at Frontier Medicines Corp., Director at Black Belt Therapeutics Ltd., and Director at DF II LP NV.
He is also the Managing Partner at DROIA NV since 2013.
Previously, he worked as an Investment Manager at Waterland Private Equity NV from 2008 to 2013.
He was also a Director at NormOxys, Inc., Tusk Therapeutics Ltd., and served as an Independent Director at Cyteir Therapeutics, Inc. from 2019 to 2022.
Naesens holds an MBA from INSEAD and an undergraduate degree from Katholieke Universiteit Leuven.
Actieve functies van Janwillem Naesens
| Bedrijven | Functie | Begin |
|---|---|---|
Convert Pharmaceuticals SA
 Convert Pharmaceuticals SA Miscellaneous Commercial ServicesCommercial Services Convert Pharmaceuticals SA provides preclinical stage drug development services. Its product hypoxia activated prodrug (HAP) is a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. The company was founded by Philippe Lambin, Nicolas Geuens, and Paul Tulcinsky on February 24, 2017 and is headquartered in Liege, Belgium. | Chief Executive Officer | - |
DROIA NV
 DROIA NV Investment ManagersFinance DROIA NV (DROIA) is an Independent Venture Capital firm founded in 2011 by Bart van Hooland. The firm is headquartered in Meise with additional office in Luxembourg. | Private Equity Investor | 01-09-2013 |
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Director/Board Member | - |
DF II LP NV
 DF II LP NV Financial ConglomeratesFinance DF II LP NV is a private company based in Meise, Belgium. The Belgian company was founded in 2018. | Director/Board Member | - |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Director/Board Member | - |
OCTIMET Oncology NV
 OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Director/Board Member | - |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Director/Board Member | - |
Black Belt Therapeutics Ltd.
 Black Belt Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Black Belt Therapeutics Ltd. is a British biotechnology company. | Director/Board Member | - |
Eerdere bekende functies van Janwillem Naesens
| Bedrijven | Functie | Einde |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Director/Board Member | 15-06-2022 |
| ░░░░░░░░░ ░░░░░░░ ░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Opleiding van Janwillem Naesens
| INSEAD | Masters Business Admin |
| Katholieke Universiteit Leuven | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 11 |
|---|---|
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Health Technology |
| Waterland Private Equity NV | Finance |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Health Technology |
DROIA NV
DROIA NV Investment ManagersFinance DROIA NV (DROIA) is an Independent Venture Capital firm founded in 2011 by Bart van Hooland. The firm is headquartered in Meise with additional office in Luxembourg. | Finance |
Tusk Therapeutics Ltd.
 Tusk Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom. | Health Technology |
OCTIMET Oncology NV
OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Health Technology |
Highlight Therapeutics SL
Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Health Technology |
Convert Pharmaceuticals SA
Convert Pharmaceuticals SA Miscellaneous Commercial ServicesCommercial Services Convert Pharmaceuticals SA provides preclinical stage drug development services. Its product hypoxia activated prodrug (HAP) is a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. The company was founded by Philippe Lambin, Nicolas Geuens, and Paul Tulcinsky on February 24, 2017 and is headquartered in Liege, Belgium. | Commercial Services |
Frontier Medicines Corp.
Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Health Technology |
Black Belt Therapeutics Ltd.
Black Belt Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Black Belt Therapeutics Ltd. is a British biotechnology company. | Commercial Services |
DF II LP NV
DF II LP NV Financial ConglomeratesFinance DF II LP NV is a private company based in Meise, Belgium. The Belgian company was founded in 2018. | Finance |
